Antiemetics: Nausea & Vomiting Flashcards
List SEVEN major classes of drugs used for the treatment of nausea and vomiting.
(1) Serotonin 5-HT3 antagonists (Ondansetron, Granisetron, Palanosetron)
(2) Corticosteroids (Dexamethaosone, Methylprednisolone)
(3) Neurokinin receptor antagonists (Aprepitant, Fosaprepitant, “pitant)
(4) Dopamine receptor antagonists (Metoclopramide, Promethazine, Olanzapine)
(5) Muscarinic receptor antagonists (Anticholinergics), for motion sickness (Hyoscine)
(6) H1 histamine receptor antihistamines - e.g. Cinnarizine
(7) Benzodiazepines - Lorazepam, “azepam, “zolam
Serotonin, Dopamine, Neurokinin,
Coricosteroids, Anticholinergics, CNS
Name TWO examples of antiemetic serotonin 5-HT3 antagonists
Ondansetron, granisetron, palonosetron, and other *setrons
Name an example of (1) a first-generation and (2) a second-generation 5-HT3 antagonist anti-emetic. State the half-life of these drugs.
(1) First-generation:
* Ondansetron (half-life 4-9 hrs)
(2) Second-generation:
- Granisetron: half-life 9-12 hrs in cancer patients
- Palonosetron: half-life 40-50 hrs
Briefly describe the mechanism of action of 5-HT3 antagonist antiemetics and describe their use in the treatment of chemotherapy-induced nausea and vomiting.
- Act at 5-HT3receptors primarily in the GIT
- CNS 5-HT3receptors do not appear to play an important role in actions in nausea and vomiting
- Efficacy enhanced by combination with a corticosteroid and NK1-receptor antagonist
- Intravenously 30 min before or orally 1 hour before chemotherapy to prevention of acute chemotherapy-induced nausea and vomiting (CINV).
- Generally not effective for delayed nausea and vomiting (>24 hr after chemotherapy)
Name an example of a corticosteroid used in the treatment of chemotherapy-induced nausea and vomiting. (CINV)
Dexamethasone, methylprednisolone
Briefly discuss the adverse effects of corticosteroids used as antiemetics for chemotherapy-induced nausea and vomiting.
Major concerns / adverse effects:
- Unlikely to occur with short-term use
- Higher doses or longer-term use (> 2 weeks) may cause iatrogenic Cushing’s syndrome, including:
- Redistribution of fat (rounded face)
- Muscle wasting
- Thinning of skin, easy bruising
- Hyperglycaemia, later diabetes
- Osteoporosis
- Immunosuppression
Name an example of a dopamine receptor antagonist used as an antiemetic.
Metoclopramide
Describe the mechanism of action of dopamine receptor antagonists as antiemetics
Dopamine, especially dopamine D2, receptor antagonism in the chemoreceptor trigger zone (CTZ).
Discuss the adverse effects of dopamine receptor antagonists.
- Major concerns / adverse effects:
- Extrapyramidal side effects:
- Restlessness, dystonia, and parkinsonian symptoms
- The elderly are especially susceptible
- On long-term treatment, irreversible tardive dyskinesia can develop
- Therefore, only used short-term
- Elevated prolactin levels can cause:
- Galactorrhoea, gynaecomastia, impotence and menstrual disorders
What are the recommended options for the treatment of acute nausea and vomiting induced by a chemotherapy regimen expected to have low emetogenic risk?
A 5-HT3 receptor antagonists OR dexamethasone OR a dopamine receptor antagonist
What are the recommended options for the treatment of acute nausea and vomiting induced by a chemotherapy regimen expected to have moderate emetogenic risk (other than carboplatin)?
5-HT3 receptor antagonist AND dexamethasone
What are the recommended options for the treatment of acute nausea and vomiting induced by a chemotherapy regimen expected to have a high emetogenic risk or carboplatin?
5-HT3 receptor antagonist AND dexamethasone AND neurokinin NK1 receptor antagonist
Name an example of a neurokinin 1 (NK1) receptor antagonist used to treat nausea and vomiting.
Aprepitant, fosaprepitant or any other *pitant
Discuss the routes of administration of aprepitant and fosaprepitant.
Aprepitant is administered oral. Fosaprepitant is an intravenously administered prodrug of aprepitant.
Briefly explain the mechanism of action of neurokinin NK1 receptor antagonists in treating nausea and vomiting.
Neurokinin NK1 receptor antagonists directly antagonize NK1 receptors in the chemoreceptor trigger zone of the area postrema.